| 2023-12-18 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2023-11-14 |
详情>>
股本变动：
变动后总股本939.79万股
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.86美元,归母净利润-2081.5万美元,同比去年增长52.81%
|
| 2023-09-25 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.29美元,归母净利润-1628.9万美元,同比去年增长47.52%
|
| 2023-05-08 |
详情>>
业绩披露：
2023年一季报每股收益-0.26美元,归母净利润-1420.4万美元,同比去年增长7.47%
|
| 2023-04-27 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.To elect M. Cantey Boyd, Rohan Palekar, and Todd S. Simpson as Class III directors of the Company to hold office until the 2026 Annual Meeting of Stockholders.
2.To approve, at the discretion of the Company’s Board of Directors (the “Board”), an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-5, with the exact ratio to be set within that range at the discretion of the Board of Directors prior to the one-year anniversary of the Annual Meeting without further approval or authorization of the stockholders, and a corresponding reduction in the number of authorized shares of common stock (the “Reverse Stock Split Amendment”).
3.To approve an amendment to the Company’s Certificate of Incorporation to permit the exculpation of officers from personal liability for certain breaches of the duty of care (the “Exculpation Amendment”).
4.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
5.To approve, by a non-binding advisory vote, the compensation paid by the Company to its named executive officers.
6.To conduct any other business properly brought before the meeting.
|
| 2023-03-20 |
详情>>
业绩披露：
2022年年报每股收益-1.04美元,归母净利润-5755.7万美元,同比去年增长5.17%
|
| 2022-11-15 |
复牌提示：
2022-11-14 16:00:12 停牌，复牌日期 2022-11-14 16:30:00
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.8美元,归母净利润-4411.2万美元,同比去年增长3.10%
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.56美元,归母净利润-3103.9万美元,同比去年增长-3.19%
|
| 2022-08-09 |
财报披露：
美东时间 2022-08-09 盘后发布财报
|
| 2022-05-09 |
详情>>
业绩披露：
2022年一季报每股收益-0.28美元,归母净利润-1535.1万美元,同比去年增长-2.68%
|
| 2022-03-31 |
股东大会：
将于2022-05-12召开股东大会
会议内容 ▼▲
- 1.To elect Jonathan G. Drachman and Sarah B. Noonberg as Class II directors of the Company to hold office until the 2025 Annual Meeting of Stockholders.
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.
3.To approve, by a non-binding advisory vote, the compensation paid by the Company to its named executive officers.
4.To conduct any other business properly brought before the meeting.
|
| 2022-03-01 |
详情>>
业绩披露：
2021年年报每股收益-1.1美元,归母净利润-6069.2万美元,同比去年增长-82.38%
|
| 2021-11-04 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.83美元,归母净利润-4552.5万美元,同比去年增长-120.6%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-0.55美元,归母净利润-3007.9万美元,同比去年增长-63.58%
|
| 2021-03-31 |
股东大会：
将于2021-05-13召开股东大会
会议内容 ▼▲
- 1.To elect Martin Babler, Erin Lavelle and Lewis T. “Rusty” Williams as Class I directors of the Company to hold office until the 2024 Annual Meeting of Stockholders.
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
3.To approve amendments to our 2014 Equity Incentive Plan.
4.To approve, by a non-binding advisory vote, the compensation paid by the Company to its named executive officers.
5.To conduct any other business properly brought before the meeting.
|
| 2020-03-24 |
股东大会：
将于2020-05-05召开股东大会
会议内容 ▼▲
- 1.To elect M. Cantey Boyd and Todd Simpson as Class III directors of the Company to hold office until the 2023 Annual Meeting of Stockholders.
2.To approve the Company’s 2020 Employee Stock Purchase Plan.
3.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
4.To approve, by a non-binding advisory vote, the compensation paid by the Company to its named executive officers.
5.To hold a non-binding advisory vote on whether future non-binding advisory votes on the compensation paid by the Company to its named executive officers should be held every one, two or three years.
6.To conduct any other business properly brought before the meeting.
|
| 2019-10-02 |
股东大会：
将于2019-11-12召开股东大会
会议内容 ▼▲
- 1.To elect Jonathan G. Drachman and Sarah B. Noonberg as Class II directors of the Company to hold office until the 2022 Annual Meeting of Stockholders.
2.To approve the conversion of 101,927 shares of our non-voting convertible preferred stock issued to the former equity holders of Neoleukin Therapeutics, Inc. (“Former Neoleukin”) in connection with our completed acquisition of Former Neoleukin, into 10,192,700 shares of our common stock (the “Preferred Stock Conversion Proposal”).
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 (the “Authorized Common Stock Proposal”).
4.To approve, at the discretion of the Board of Directors, an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-5, with the exact ratio to be set within that range at the discretion of our board of directors before December 31, 2020 without further approval or authorization of our stockholders, and a corresponding reduction in the number of authorized shares of common stock (the “Reverse Stock Split Proposal”).
5.To approve amendments to our 2014 Equity Incentive Plan to, among other things, increase the number of shares of our common stock available for grant and issuance thereunder by 4,500,000 shares (the “Equity Plan Proposal”).
6.To ratify the appointment of Deloitte LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
7.To approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Proposal Nos. 1 through 6 at the time of the Annual Meeting or in the absence of a quorum (the “Adjournment Proposal”).
8.To conduct any other business properly brought before the meeting.
|
| 2019-08-08 |
详情>>
内部人交易：
DRACHMAN JONATHAN G共交易2笔
|
| 2018-03-26 |
股东大会：
将于2018-05-07召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for director named herein to the Board of Directors to hold office until the 2021 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Deloitte LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.
3.To conduct any other business properly brought before the meeting.
|
| 2017-03-28 |
股东大会：
将于2017-05-08召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for director named herein to the Board of Directors to hold office until the 2020 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Deloitte LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017.
3.To conduct any other business properly brought before the meeting.
|
| 2016-03-25 |
股东大会：
将于2016-05-09召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for director named herein to the Board of Directors to hold office until the 2019 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Deloitte LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
3.To conduct any other business properly brought before the meeting.
|
| 2015-03-27 |
股东大会：
将于2015-05-11召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for director named herein to the Board of Directors to hold office until the 2018 Annual Meeting of Stockholders.
2.To ratify the selection by the Audit Committee of the Board of Directors of Deloitte LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2015.
3.To conduct any other business properly brought before the meeting.
|